Command Palette

Search for a command to run...

AMBUJACEM

613.2516.55 (2.77%)

Quarterly ResultsProfit & LossBalance SheetCash Flow

Key Insights

POSITIVE
  • Net Sales increased significantly to ₹9888.61 crore in Q1 2025, showing strong demand recovery.
  • Operating profit improved to ₹1066.91 crore, indicating better cost management and efficiency.
  • Net profit surged to ₹1282.24 crore, reflecting enhanced profitability compared to earlier quarters.
NEGATIVE
  • Company experienced a cash flow shortfall with a 10% decrease this year [Dummy Data]
  • Company’s strategic partnerships have yet to generate expected growth. [Dummy Data]
  • Company’s EBITDA shrank at a CAGR of -8% over the past 3 years. [Dummy Data]
Quarterly Results Data
FieldTrendJun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25
Revenue
8,712.907,423.958,128.808,893.998,311.487,516.119,328.569,888.61
Expenses
7,469.746,564.286,884.547,741.317,566.917,023.498,347.688,821.70
Operating Profit
1,243.16859.671,244.261,152.68744.57492.62980.881,066.91
Other Income
263.24476.04193.65233.46354.72374.031,352.24573.26
Interest
52.0761.2570.1492.9167.8166.8566.9914.29
Depreciation
371.72380.90417.70453.06467.43551.96663.98786.35
Profit Before Tax
1,511.661,339.711,448.121,601.141,102.68712.672,336.071,779.56
Tax
376.20352.47358.5775.36313.05239.78-284.02497.32
Net Profit
1,135.46987.241,089.551,525.78789.63472.892,620.091,282.24
EPS in Rs
4.563.994.145.312.671.858.593.88